PANCRYOS
PANCRYOS is a spin-out arising from the Novo Nordisk Foundation Center for Stem Cell Biology (DanStem) at the University of Copenhagen. The company is aiming to develop a next generation stem cell derived allogeneic cell therapy (PanINSULA™) for type 1 diabetes. Based on novel IP, PANCRYOS will – for the first time – enable the definitive safety and large scale manufacturing of insulin cells for therapeutic use. PANCRYOS is in the pre-clinical stage of development and is addressing cost effective scalability and manufacturing of the cell therapy early on to ensure successful commercialization.
PANCRYOS
Industry:
Biopharma Biotechnology
Founded:
2014-01-01
Address:
Copenhagen, Hovedstaden, Denmark
Country:
Denmark
Website Url:
http://www.pancryos.com
Total Employee:
1+
Status:
Active
Total Funding:
71.43 K EUR
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API LetsEncrypt Apple Mobile Web Clips Icon WordPress Apache Mobile Non Scaleable Content
Current Employees Featured
Jacqueline Ameri Co-Founder and CEO @ PanCryos
Co-Founder and CEO
2015-01-01
Henrik Semb Co-Founder @ PanCryos
Co-Founder
Founder
Investors List
EASME - EU Executive Agency for SMEs
EASME - EU Executive Agency for SMEs investment in Grant - PanCryos
Official Site Inspections
http://www.pancryos.com Semrush global rank: 2.31 M Semrush visits lastest month: 8.09 K
- Host name: linux165.unoeuro.com
- IP address: 94.231.103.188
- Location: Denmark
- Latitude: 55.7123
- Longitude: 12.0564
- Timezone: Europe/Copenhagen
More informations about "PanCryos"
Pancryos | Insulin Naturally
Pancryos is a spin out from the University of Copenhagen based on research conducted at the Novo Nordisk Foundation Center for Stem Cell Biology (DanStem). MORE Pancryos is …See details»
COMPANY | Pancryos
PANCRYOS is a spin-out arising from the Novo Nordisk Foundation Center for Stem Cell Biology (DanStem) at the University of Copenhagen. The company is aiming to develop a next …See details»
PanCryos - Crunchbase Company Profile & Funding
PANCRYOS is a spin-out arising from the Novo Nordisk Foundation Center for Stem Cell Biology (DanStem) at the University of Copenhagen. The company is aiming to develop a next …See details»
PanCryos - Overview, News & Similar companies | ZoomInfo.com
May 24, 2022 Who is PanCryos. PanCryos ApS is a Danish pre-clinical stage biotech company developing a best-in-class stem cell based allogeneic beta cell therapy - PanINSULA to treat …See details»
PanCryos - VentureRadar
It has particular expertise in cell isolation and quality control, stem/precursor cell characterization and differentiation, preparation of standardized beta cell grafts and organization and funding of …See details»
PanCryos - LinkedIn
PanCryos Biotechnology Research Copenhagen N, Capital Region 1,012 followers Dedicated to improving life quality for millions of people suffering from diabetesSee details»
PanCryos - Products, Competitors, Financials, Employees, …
PanCryos is a biotechnology company focused on developing a next-generation stem cell derived therapy for diabetes. Use the CB Insights Platform to explore PanCryos's full profile. ...See details»
PanCryos Company Profile 2024: Valuation, Funding & Investors
PanCryos General Information Description. Developer of next-generation stem cell therapy designed to offer treatment for one diabetes. The company's therapy has been designed by …See details»
Pancryos - Company Profile - Tracxn
Nov 27, 2024 Pancryos - Provider of stem cell-derived cell therapy for diabetic patients. Raised funding over 3 rounds from 3 investors. Valued at $6.38K. Founded by Jacqueline Ameri and …See details»
PanCryos Company Profile - Office Locations, Competitors ... - Craft
PanCryos has 5 employees across 2 locations and $83.6 k in total funding,. See insights on PanCryos including office locations, competitors, revenue, financials, executives, subsidiaries …See details»
Takara Bio Europe AB and PanCryos announce licensing …
PanCryos has established a simplified and effective method to generate stem cell-derived, glucose-responsive beta cells and is one of several customers in TBEAB’s new out-licensing …See details»
PanCryos | DANISH BIO - Dansk Biotek
PanCryos is dedicated to developing a safe, scalable, and cost-efficient cell replacement therapy to improve quality of life of millions of people suffering from insulin-dependent diabetes. …See details»
PanCryos - Contacts, Employees, Board Members, Advisors & Alumni
Organization. PanCryos . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. Highlights. Employee Profiles 2. About. PanCryos has 2 …See details»
PanCryos - Updates, News, Events, Signals & Triggers - Crunchbase
PanCryos develops a next generation stem cell derived allogenic cell therapy or Type 1 diabetes.See details»
Pancryos - NOME
Pancryos Pancryos is dedicated to developing a safe and cost-efficient cell therapy to improve the quality of life of millions of people suffering from insulin-dependent diabetes. Pancryos has …See details»
NEWS - Pancryos
We are grateful to Innovation Fund Denmark for awarding an Innobooster grant to PanCryos. The grant will co-fund our ongoing effort to develop a curative stem cell-based therapy for type 1 …See details»
Exclusive global license agreement for first in class ...
May 24, 2022 We are very happy to announce a global exclusive license with Brigham and Women’s Hospital for the first in class convection-enhanced macroencapsulation device …See details»
TECHNOLOGY - Pancryos
In collaboration with Professor Raphaël Scharfmann’s team at INSERM, Paris, PANCRYOS founders Jacqueline Ameri and Henrik Semb recently also published a follow-up study entitled …See details»
300 Years of Leadership and Innovation | Pancryos
Delighted to have Pancryos featured in the official History of Parliament Trust 300 Years of Leadership and Innovation commemorative album, celebrating leadership and pioneering …See details»